Expression of TWEAK and Its Receptor CD163 in Peripheral Blood of Psoriasis Vulgaris (PV)
Abstract
To investigate serum levels and mRNA expressions of tumor necrosis factor-like weak inducer of apoptosis （TWEAK） and its receptor CD163 from the patients with psoriasis vulgaris (PV). Methods Peripheral blood samples were obtained from 28 patients with PV and 15 healthy control subjects. Serum levels of TWEAK and CD163 were detected by ELISA, mRNA expressions of TWEAK and CD163 in peripheral blood were analyzed by real time-PCR, and protein expressions of TWEAK and CD163 were determined by flow cytometry. Results All the 28 PV patients were in progressive stage at the beginning of this study, 10 patients then recovered in convalescent stage after treatment. Compared to healthy controls, PV patients had higher serum TWEAK levels and lower serum CD163 levels. Serum TWEAK level in progressive stage was significantly higher than that in convalescent stage. Serum CD163 level were elevated significantly in convalescent stage compared with those in progressive stage. TWEAK mRNA expression in PV patients were significantly lower than that in healthy controls, but there was no significant differences of CD163 mRNA expression. TWEAK expression in monocytes in progressive stage and convalescent stage were significantly higher than that of controls, CD163 expression in monocytes in progressive stage and convalescent stage significantly lower than that in controls. No correlations wene found between psoriasis area and severity index (PASI) score and expression of TWEAK and CD163. Conclusion TWEAK/CD163 pathway may play a role in PV.
Keywords: TWEAK, CD163, Psoriasis vulgaris
Full Text:
PDFReferences
CHICHEPORTICHE Y, BOURDON PR. XU H, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem, 1997. 272 (51):32401-32410.
ZIMMERMANN M, KORECK A, MEYER N, et al. TNF- like weak inducer of apoptosis ( TWEAK ) and TNF-a cooperate in the induction of keratinocyte apoptosis. J Allergy Clin Immunol .2011.127(1) s 200-207.
MORENO J A, DEJOUVENCEL T, LABREUCHE J. et al. Peripheral artery disease is associated with a high 0)163/ TWEAK plasma ratio. Arterioscler Thromb Vase Biol. 2010. 30(6);1253-1262.
LLAURADOG, GONZALEZ-CLEMENTEL JM, MAYMO- MASIP E. et al. Serum levels of TWP'AK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. A case-control study. PLoS One. 2012,7(8): e43919[2017-12-13]. https;// doi.org/10.1371/ journal, pone. 0043919.
VALDIVIELSO JM, COLL B. MARTIN-VENTURA JL, et al. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease. J Nephrol. 2013. 26 (6)j1105-1113.
URBONAVICIENE G, MARTIN-VENTURA JL, LINDHOLT JS. et al. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis. 2011,219(2):892-899.
BILGIC О, SIVRIKAYAI A, TOKER A, et al. Serum levels of TWEAK in patients with psoriasis vulgaris. Cytokine,2016,77( 1): 10-13.
GIBBS S. Skin disease and socioeconomic conditions in rural Africa Tanzania. Int J Dermatol,1996,35(9);633-639.
DANIELSEN K. OLSEN AO, WILSGAARD T, et al. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol, 2013, 168 ( 6): 1303-1310.
BALI WAG J, BARNES DH, JOHNSTON A. Cytokines in psoriasis. Cytokine,2015,73(2);342-350.
XIA L, SHEN H, XIAO W, et al. Increased serum TWEAK levels in psoriatic arthritis; relationship with disease activity and matrix metalloproteinase-3 serum levels. Cytokine,2011,53(3): 289-291.
MEYER T, AMAYA M. DESAI H. et al. Human platelets contain and release TWEAK. Platelets, 2010, 21 ( 7 ); 571- 574.
NAKAYAMAM, KAYAGAKI N, YAMAGUCHI N, et al. Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med,2000,192(9); 1373-1380.
FEIGHERY C, DUNNE J, BINGHAM EA, et al. Evaluation of soluble CD163 as a marker of inflammation in psoriasis. Clin Exp Dermatol,2011 ,36(2) :201-203.
SUGAYA M, MIYAGAKI T, OHMATSU H, et al. Association of the numbers of CD1634* cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci, 2012,68( 1);45- 51.
AKAHORI H, KARMALI V, POLAVARAPU R, et al. CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury. Nat Commun, 2015, 6; 7792 2017-12- 13 https;//www. ncbi. nlm. nih. gov/pmc/articles/ PMC4918310/pdf/ncomms8792. pdf. doi; 10. 1038/ ncomms8792.
BOVER LC, CARDO-VILA M, KUNIYASU A, et al. A previously unrecognized protein-protein interaction between TWEAK and CD163; potential biological implications. J Immunol.2007,178( 12) .8183-8194.
KUJI S, HI RASH IMA Y. KOMEDA S. et al. The relationship between positive peritoneal cytology and the prognosis of patients with FIGO stage I / II uterine cervical cancer. J Gynecol Oncol,2014*25(2);90-96.
YAOY, LI C ZHOU X, et al. PIWIL2 induces c-myc expression by interacting with NME2 and regulates c-myc- mediated tumor cell proliferation. Oncotarget, 2014 , 5 ( 18 ): 8466-8477.
CHANETON B. HILLMANN P, ZHENG L, et al. Serine is a natural ligand and allosteric activator of pyruvate kinase М2. Nature,2012,491(7424) :458-462.
BIBLE E. Neuro-oncology: BCAT1 promotes cell proliferation in aggressive gliomas. Nat Rev Neurol, 2013, 9 (8): 420 [2017-12-13]. https://www. nature, com/articles/ nrneurol. 2013. 135. doi;10. 1038/nrneurol. 2013. 135.
NIWA O.KUMAZAKI T.TSUKIYAMA T.et al. A cDNA clone overexpressed and amplified in a mouse teratocareinoma line. Nucleic Acids Res, 1990,18(22):6709-6709.
COLE DJ,BROWN DS, CROSSLEY E.et at. Carcinoma of the cervix uteri: an assessment of the relationship of tumor proliferation to prognosis. Br J Cancer, 1992,65(5) ;783-785.
WANG ZQ, DNEN FADDAOUI A, BACHVAROVA M.et al. BCAT1 expression associates with ovarian cancer progression; possible implications in altered disease metabolism. Oncotarget,2015,6(31);31522-31543.
Refbacks
- There are currently no refbacks.
